Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Obicetrapib in ASCVD (Cardiovascular Outcomes). The expected timing is based on the latest available company guidance and may change.
PREVAIL (CVOT) tral. 4/2024– Enrollment completed, ongoing event-driven CVOT. Final readout in 2026. 11/05/25:- PREVAIL CVOT ongoing with over 9,500 patients; enrollment completed April 2024, event-driven outcomes. 02/18/26:- PREVAIL CV outcomes trial ongoing; 12-month blinded event rate similar to BROADWAY; event-driven outcomes readout still expected 2026. 05/07/26:- PREVAIL interim analysis planned Q4 2026; result expected Q1 2027; trial completion anticipated by end 2027. 08/05/26:- PREVAIL interim analysis remains planned Q4 2026; result expected Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.